LBX Pharmacy Chain Joint Stock Company (SHA:603883)
China · Delayed Price · Currency is CNY 12.26
+0.18 (1.49%)
May 29, 2026, 3:00 PM CST
SHA:603883 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 22,166 | 22,120 | 22,213 | 22,288 | 20,055 | 15,579 |
Other Revenue | 116.57 | 116.57 | 144.48 | 149.26 | 120.29 | 117.11 |
| 22,283 | 22,237 | 22,358 | 22,437 | 20,176 | 15,696 | |
Revenue Growth (YoY) | 0.13% | -0.54% | -0.36% | 11.21% | 28.54% | 12.38% |
Cost of Revenue | 15,133 | 15,064 | 14,946 | 15,157 | 13,751 | 10,659 |
Gross Profit | 7,150 | 7,173 | 7,412 | 7,280 | 6,425 | 5,037 |
Selling, General & Admin | 5,945 | 5,987 | 6,205 | 5,753 | 5,005 | 3,990 |
Research & Development | 54.76 | 51.07 | 2.01 | 2.51 | 2.23 | - |
Other Operating Expenses | 27.17 | 25.09 | 33.68 | 46.21 | 38.51 | 14.95 |
Operating Expenses | 6,045 | 6,082 | 6,247 | 5,811 | 5,053 | 4,010 |
Operating Income | 1,104 | 1,091 | 1,165 | 1,469 | 1,371 | 1,027 |
Interest Expense | -120.49 | -130.27 | -178.25 | -185.6 | -232.14 | -192.13 |
Interest & Investment Income | 13.54 | 14.27 | 22.83 | 93.87 | 51.35 | 37.14 |
Currency Exchange Gain (Loss) | - | - | -1.25 | -5.22 | -16.91 | 4.8 |
Other Non Operating Income (Expenses) | -19.51 | -17.43 | -13.65 | -14.61 | -13.4 | -14.44 |
EBT Excluding Unusual Items | 977.74 | 957.59 | 994.5 | 1,357 | 1,160 | 861.9 |
Impairment of Goodwill | -150.34 | -150.34 | -107.54 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | -1.5 | 5.77 | 10.47 |
Gain (Loss) on Sale of Assets | -3.87 | -3.54 | -4.53 | 5.51 | 1.44 | 4.66 |
Asset Writedown | -88.07 | -88.26 | - | - | - | - |
Other Unusual Items | 40.29 | 40.72 | 33.54 | 46.69 | 40.21 | 84.95 |
Pretax Income | 775.75 | 756.17 | 915.97 | 1,408 | 1,208 | 961.99 |
Income Tax Expense | 220.67 | 215.72 | 230.85 | 284.27 | 231.37 | 175.26 |
Earnings From Continuing Operations | 555.08 | 540.45 | 685.12 | 1,124 | 976.24 | 786.73 |
Minority Interest in Earnings | -160.02 | -158.6 | -166.05 | -194.54 | -191.28 | -117.49 |
Net Income | 395.07 | 381.85 | 519.06 | 929.02 | 784.96 | 669.24 |
Net Income to Common | 395.07 | 381.85 | 519.06 | 929.02 | 784.96 | 669.24 |
Net Income Growth | -11.90% | -26.43% | -44.13% | 18.35% | 17.29% | 7.75% |
Shares Outstanding (Basic) | 762 | 764 | 763 | 755 | 750 | 707 |
Shares Outstanding (Diluted) | 762 | 764 | 763 | 755 | 750 | 707 |
Shares Change (YoY) | 0.04% | 0.05% | 1.06% | 0.67% | 6.08% | 2.42% |
EPS (Basic) | 0.52 | 0.50 | 0.68 | 1.23 | 1.05 | 0.95 |
EPS (Diluted) | 0.52 | 0.50 | 0.68 | 1.23 | 1.05 | 0.95 |
EPS Growth | -11.94% | -26.47% | -44.71% | 17.57% | 10.57% | 5.20% |
Free Cash Flow | 2,963 | 2,889 | 1,519 | 2,109 | 2,006 | 1,820 |
Free Cash Flow Per Share | 3.89 | 3.78 | 1.99 | 2.79 | 2.67 | 2.57 |
Dividend Per Share | 0.410 | 0.410 | 0.411 | 0.508 | 0.385 | 0.296 |
Dividend Growth | -0.17% | -0.17% | -19.11% | 32.01% | 30.02% | 42.83% |
Gross Margin | 32.09% | 32.26% | 33.15% | 32.45% | 31.84% | 32.09% |
Operating Margin | 4.96% | 4.91% | 5.21% | 6.55% | 6.80% | 6.54% |
Profit Margin | 1.77% | 1.72% | 2.32% | 4.14% | 3.89% | 4.26% |
Free Cash Flow Margin | 13.30% | 12.99% | 6.79% | 9.40% | 9.94% | 11.59% |
EBITDA | - | 1,263 | 1,403 | 1,662 | 1,533 | 1,162 |
EBITDA Margin | - | 5.68% | 6.28% | 7.41% | 7.60% | 7.41% |
D&A For EBITDA | - | 171.99 | 238.43 | 193.69 | 161.87 | 135.67 |
EBIT | 1,104 | 1,091 | 1,165 | 1,469 | 1,371 | 1,027 |
EBIT Margin | 4.96% | 4.91% | 5.21% | 6.55% | 6.80% | 6.54% |
Effective Tax Rate | 28.44% | 28.53% | 25.20% | 20.19% | 19.16% | 18.22% |
Revenue as Reported | 22,283 | 22,237 | 22,358 | 22,437 | 20,176 | 15,696 |
Advertising Expenses | - | 101.47 | 115.57 | 117.99 | 94.5 | 109.84 |